Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE(®)) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Phil...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Drug Saf
Главные авторы: Stein, Anthony, Franklin, Janet L., Chia, Victoria M., Arrindell, Deborah, Kormany, William, Wright, Jacqueline, Parson, Mandy, Amouzadeh, Hamid R., Choudhry, Jessica, Joseph, Guiandre
Формат: Artigo
Язык:Inglês
Опубликовано: Springer International Publishing 2018
Предметы:
Review Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6475509/
https://ncbi.nlm.nih.gov/pubmed/30565020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40264-018-0760-1
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы